Loading
Adipokines, Inflammation, and Metabolic Diseases · Journal article
International Journal of Molecular Medicine · September 3, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review article synthesizing recent molecular evidence on how programmed cell death pathways (apoptosis, pyroptosis, autophagy, ferroptosis, necroptosis, PANoptosis, disulfidptosis) contribute to metabolic syndrome pathogenesis and may be therapeutic targets. The article presents no primary empirical data, clinical trials, or quantified outcomes; it proposes theoretical directions for future drug development.
Narrative review article. Patients with metabolic syndrome (insulin resistance, central obesity, hyperglycemia, hypertension, dyslipidemia).
Programmed cell death is identified as a key driver of inflammation and central to metabolic syndrome development and progression Current therapeutic approaches (weight reduction, physical activity, pharmacological lipid/blood pressure/glucose management) show suboptimal efficacy Seven forms of programmed cell death are reviewed for their molecular mechanisms, tissue-specific functions, and regulatory crosstalk in metabolic syndrome
Current therapeutic approaches (weight reduction, physical activity, pharmacological lipid/blood pressure/glucose management) show suboptimal efficacy
This review outlines a mechanistic rationale for targeting programmed cell death pathways in metabolic syndrome, but provides no clinical evidence that such interventions are efficacious or safe in humans. Clinicians should recognize this as early-stage theoretical work requiring validation in experimental and clinical studies before translation to practice.
This is a narrative review synthesizing mechanistic evidence about programmed cell death in metabolic syndrome, raising therapeutic hypotheses rather than testing them or reporting clinical outcomes.
As stated by the source record.
This review outlines a mechanistic rationale for targeting programmed cell death pathways in metabolic syndrome, but provides no clinical evidence that such interventions are efficacious or safe in humans. Clinicians should recognize this as early-stage theoretical work requiring validation in experimental and clinical studies before translation to practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Metabolic syndrome (MetS) is a clinical syndrome primarily characterized by insulin resistance, integrating central obesity, hyperglycemia, hypertension and dyslipidemia.It is associated with increased risks of type 2 diabetes mellitus, non-alcoholic fatty liver disease and atherosclerosis.due to its high prevalence, complex pathogenesis and lack of effective treatments, MetS has become a notable global health issue.current therapeutic approaches mainly emphasize weight reduction through caloric restriction and increased physical activity, or pharmacological interventions to improve lipid profiles, blood pressure and blood glucose; however, their efficacy remains suboptimal.Growing evidence indicates that programmed cell death (PCD), as a key driver of inflammation, serves a crucial role in the development and progression of MetS.The present review provides a comprehensive overview of recent advances in the understanding of how established and emerging forms of Pcd contribute to MetS pathogenesis, including apoptosis, pyroptosis, autophagy, ferroptosis, necroptosis, PANoptosis and disulfidptosis.Particular emphasis is placed on their molecular mechanisms, tissue-specific functions, regulatory crosstalk and therapeutic potential.Additionally, the present review discusses novel regulatory approaches and potential therapeutic strategies based on Pcd network intervention, offering theoretical foundations and directions for developing innovative therapies to prevent and treat MetS and its complications.Contents 1. Introduction 2. Methods 3. Pathophysiological mechanisms of MetS 4. Pcd in MetS 5. Molecular crosstalk and network regulation among Pcd pathways in MetS 6. Research on novel regulatory mechanisms in MetS 7. Therapeutic strategies targeting Pcd: From experimental evidence to clinical translation 8. conclusions and outlook
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.